Imsidolimab + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acneiform Eruptions
Conditions
Acneiform Eruptions
Trial Timeline
May 4, 2021 → Dec 13, 2021
NCT ID
NCT04697069About Imsidolimab + Placebo
Imsidolimab + Placebo is a phase 2 stage product being developed by Vanda Pharmaceuticals for Acneiform Eruptions. The current trial status is terminated. This product is registered under clinical trial identifier NCT04697069. Target conditions include Acneiform Eruptions.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04856930 | Phase 2 | Completed |
| NCT04856917 | Phase 2 | Completed |
| NCT04697069 | Phase 2 | Terminated |
| NCT04697056 | Phase 2 | Terminated |
| NCT03633396 | Phase 2 | Completed |
Competing Products
2 competing products in Acneiform Eruptions
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 Placebo | Hoth Therapeutics | Phase 2 | 44 |
| Topical Dapsone 5% Gel + oral antibiotics | Bristol Myers Squibb | Phase 3 | 76 |